Conversion Labs (OTCMKTS:CVLBD – Get Rating) is one of 30 publicly-traded companies in the “Miscellaneous Manufacturing Industries” industry, but how does it compare to its rivals? We will compare Conversion Labs to similar companies based on the strength of its dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.
Earnings & Valuation
This table compares Conversion Labs and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Conversion Labs | $12.47 million | -$3.14 million | -2.60 |
| Conversion Labs Competitors | $1.67 billion | $157.67 million | 7.00 |
Conversion Labs’ rivals have higher revenue and earnings than Conversion Labs. Conversion Labs is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
0.3% of Conversion Labs shares are held by institutional investors. Comparatively, 31.1% of shares of all “Miscellaneous Manufacturing Industries” companies are held by institutional investors. 41.9% of Conversion Labs shares are held by company insiders. Comparatively, 19.3% of shares of all “Miscellaneous Manufacturing Industries” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Volatility and Risk
Conversion Labs has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Conversion Labs’ rivals have a beta of -0.23, suggesting that their average share price is 123% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for Conversion Labs and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Conversion Labs | 0 | 0 | 0 | 0 | N/A |
| Conversion Labs Competitors | 59 | 169 | 420 | 11 | 2.58 |
As a group, “Miscellaneous Manufacturing Industries” companies have a potential upside of 6.50%. Given Conversion Labs’ rivals higher probable upside, analysts clearly believe Conversion Labs has less favorable growth aspects than its rivals.
Profitability
This table compares Conversion Labs and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Conversion Labs | -35.92% | N/A | -260.09% |
| Conversion Labs Competitors | -154.94% | -9.07% | -11.88% |
Summary
Conversion Labs rivals beat Conversion Labs on 6 of the 10 factors compared.
Conversion Labs Company Profile
Conversion Labs, Inc. engages in the manufacturing, distribution, and sale of natural immune support products containing proprietary yeast beta glucans. Its products are oral intake tablets and topical creams, and gels for skin application. It operates through the Finished Cosmetic Products and Nutraceutical and Cosmetic Additives segments. The company was founded in 1987 and is headquartered in New York, NY.
Receive News & Ratings for Conversion Labs Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Conversion Labs and related companies with MarketBeat.com’s FREE daily email newsletter.